Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
Pharmaceutical companies are not just looking for new anti-HIV medications with fewer toxicities these days'they are also developing drugs specifically designed to combat the adverse side effects linked with currently available antiretrovirals. At East Brunswick, N.J.'based Savient Pharmaceuticals, researchers are organizing a Phase II clinical trial of a medication to treat pain caused by HIV-related neuropathy. Called Prosaptide, the drug is a peptide derived from the human growth protein prosaposin. Since it is a natural compound, it is believed to be free of the side effects caused by other types of pain medications. Peripheral neuropathy'usually marked by pain, tingling, or loss of feeling in the hands and feet'is relatively common among HIV-positive people and may be related to HIV disease or its treatment. Some AIDS experts worry that the longer patients take anti-HIV drugs, the greater their chances are for experiencing worsening neuropathy symptoms. Commonly used medications to treat neuropathy include opioids, anticonvulsants, and antidepressants, which can cause such adverse side effects as dizziness, drowsiness, cardiac arrhythmia, and even addiction. 'Current therapies for HIV/AIDS-related neuropathic pain include topical or oral analgesics, which have limited efficacy, or central nervous system'acting drugs, which are often accompanied by unacceptable side effects,' says Savient chairman and CEO Sim Fass. 'Our objective is to develop an analgesic product that effectively mitigates peripheral neuropathic pain without the dose-limiting side effects typical of current therapies in use.' The company began recruiting patients for the clinical trial at the end of the August and hopes to begin the efficacy test later this year.
From our Sponsors
Most Popular
The road to U=U: How science has been liberating HIV+ people for a decade
July 01 2026 12:05 PM
How to find an HIV-competent healthcare provider, according to advocates
May 19 2026 4:55 PM
Plus: Featured Video
Latest Stories
A New Once-Daily Pill to Treat HIV Just Got the FDA’s Green Light
August 31 2026 2:31 PM
Why affirming faith communities belong in the fight to end HIV
August 30 2026 8:00 AM
Navigating a new HIV diagnosis? Advocates say community is key
August 25 2026 3:33 PM
Gay Wine Weekend toasts 15 years of raising funds for HIV
August 25 2026 11:00 AM
A new HIV diagnosis doesn't have to be nerve-wracking. Advocates share their advice
July 30 2026 12:01 PM
Zero HIV Stigma Day: The epidemic we still choose to ignore
July 21 2026 7:00 AM
National HIV Prevention Day: Awareness is my superpower
July 17 2026 8:00 AM
Federal court clarifies that people with HIV can join the military again
June 03 2026 5:36 PM
Can a single infusion of immune cells suppress HIV for years?
May 11 2026 11:39 AM
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
April 29 2026 3:32 PM
National HIV advocacy group's CEO rejects claims of crisis
April 21 2026 5:14 PM
Beyond awareness: How youth leadership is reshaping the HIV response
April 10 2026 9:12 AM
Saving public health? AIDS United's new CEO has a plan
March 23 2026 9:48 AM
Struggling with daily HIV meds? Monthly shots may be the answer
March 20 2026 7:12 AM
Trending stories
Recommended Stories for You
































































